RESUMEN
OBJECTIVE: Describes the variation in prostate cancer testing by the remoteness of residence and socio-economic status groups in Australia. DESIGN: A national population-based descriptive study using Medicare data extracted by the Department of Health (formerly the Department of Health and Ageing). SETTING: Australia. PARTICIPANTS: All men, with a Medicare-reimbursed prostate-specific antigen test conducted in Australia between 2002 and 2017, were included. We focused on "screening and case finding" tests (Medicare Benefits Schedule item number 66655) from 1 April 2005 to 31 December 2009, to describe testing differences in subgroups. Groups were categorised into State and Territory, socio-economic status and region of residence. A negative binomial regression model was fitted to measure the incidence rate ratios of those who had a screening prostate-specific antigen test by group. MAIN OUTCOME MEASURES: Age-standardised testing rates and incidence rate ratios. RESULTS: Between 2002 and 2017, 11 588 775 screening prostate-specific antigen tests were reimbursed by the Department of Human Services. During 2005-2009, 52% of all Australian men, aged 40 years and over, had a screening test. The incidence rate ratios differed by State and Territory. Men aged 40 years and over, living in very remote areas, were 43% less likely to have had a screening test than residents of major cities. Prostate-specific antigen testing rates fell in all age groups between 2007 and 2009 and 2017. CONCLUSIONS: The prostate-specific antigen testing behaviour differs between community groups in Australia. Men were less likely to have had a screening prostate-specific antigen test the farther they lived from the major cities. This highlights the need for a more targeted approach to achieve an equitable and evidence-based prostate cancer care across all sectors of the community.
Asunto(s)
Tamizaje Masivo , Pautas de la Práctica en Medicina , Antígeno Prostático Específico/sangre , Servicios de Salud Rural , Clase Social , Adulto , Anciano , Australia/epidemiología , Detección Precoz del Cáncer , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Próstata/diagnósticoRESUMEN
BACKGROUND: The increase in the use of multiparametric magnetic resonance imaging for the detection of prostate cancer has led to the rapid adoption of MRI-guided biopsies (MRGBs). To date, there is limited evidence in the use of MRGB and no direct comparisons between the different types of MRGB. We aimed to assess whether multiparametric MRGBs with MRI-US transperineal fusion biopsy (FB) and cognitive biopsy (CB) improved the management of prostate cancer and to assess if there is any difference in prostate cancer detection with FB compared with CB. METHODS: Patients who underwent an MRGB and a systematic biopsy (SB) from June 2014 to August 2016 on the Central Coast, NSW, Australia, were included in the study. The results of SB were compared with MRGB. The primary outcome was prostate cancer detection and if MRGB changed patient management. RESULTS: A total of 121 cases were included with a mean age of 65.5 years and prostate-specific antigen 7.4 ng/mL. Seventy-five cases (62%) had a Prostate Imaging and Reporting Data System 4-5 lesions and 46 (38%) had a Prostate Imaging and Reporting Data System 3 lesions. Fifty-six cases underwent CB and 65 underwent FB.Of the 93 patients with prostate cancer detected, 19 men (20.5%) had their management changed because of the MRGB results. Eight men (9%) had prostate cancer detected on MRGB only and 12 men (13%) underwent radical prostatectomy or radiotherapy based on the MRGB results alone.There was a trend to a higher rate of change in management with FB compared with CB (29% vs. 18%). CONCLUSIONS: This is one of the first Australian studies to assess the utility of MRGB and compare FB with CB. MRGB is a useful adjunct to SB, changing management in over 20% of our cases, with a trend toward FB having a greater impact on patient management compared with CB.
Asunto(s)
Carcinoma de Células Escamosas/diagnóstico por imagen , Fístula Cutánea/diagnóstico por imagen , Fístula Intestinal/diagnóstico por imagen , Fístula de la Vejiga Urinaria/diagnóstico por imagen , Neoplasias de la Vejiga Urinaria/diagnóstico por imagen , Neoplasias de la Vejiga Urinaria/patología , Adulto , Carcinoma de Células Escamosas/complicaciones , Carcinoma de Células Escamosas/patología , Fístula Cutánea/etiología , Humanos , Fístula Intestinal/etiología , Masculino , Fístula de la Vejiga Urinaria/etiología , Neoplasias de la Vejiga Urinaria/complicacionesRESUMEN
PURPOSE: To compare biochemical analysis of stent encrustation with that of urinary stones from the same patient. PATIENTS AND METHODS: Any patient presenting from February to December 2000 with a symptomatic ureteral or renal calculus that necessitated stenting and delayed calculus retrieval was enrolled in the study. The stent and stone were sent to the same laboratory for qualitative and semiquantitative chemical analysis. A total of 50 stents and matched calculi were available for comparison; four stents were excluded because they had insufficient encrustation for analysis. RESULTS: Two patients had open ureterolithotomy; the remainder were treated by endoscopic or percutaneous means. Every stone containing calcium oxalate had a stent that was positive for calcium oxalate. Four uric acid stones were available for comparison, and three of the four matched stents tested positive for uric acid. CONCLUSION: Biochemical analysis of urinary stent encrustation is a good predictor of urinary stone composition, especially for calcium oxalate-containing stones. Uric acid stent encrustation is likely to occur in patients with uric acid stones.